Anthem’s outcomes research unit, HealthCore, and Novo Nordisk (NYSE:NVO) have joined forces to study Novo Nordisk’s semaglutide GLP-1 receptor agonist in people with Type 2 diabetes. The real-world trial is designed to compare the long-term effectiveness of the drug, also known as Ozempic, against 40 other medications among 2,250 adults with Type 2 diabetes. “Because the Sepra […]
Novo Nordisk
Europe OKs Novo Nordisk’s Fiasp for Insulet’s Omnipod
Insulet (NSDQ:PODD) said today that its Omnipod insulin management system is available in Europe for use with Novo Nordisk‘s (NYSE:NVO) Fiasp fast-acting insulin aspart. Novo Nordisk’s Fiasp product enters the user’s bloodstream two times faster than NovoRapid and is designed to match a healthy body’s response to a meal, according to Insulet. “The addition of Fiasp for use […]
Novo Nordisk exec: In the digital age, it’s not enough to have a better molecule
Much of Dr. Todd Hobbs’ life has centered around diabetes – he was diagnosed with Type I diabetes roughly 30 years ago and now he is the father of a child with diabetes. At his Kentucky-based primary care practice, he took on diabetic patients and helped manage their care. And when he made the jump […]
Beta Bionics wins FDA nod for home-use trial of artificial pancreas tech
Beta Bionics said this week that it won FDA approval to start recruiting patients with Type I diabetes for home-use studies of its iLet bionic pancreas system. The trial is slated to test Novo Nordisk’s fast-acting insulin, Fiasp, with the company’s autonomous infusion pump in adults with Type I diabetes. The study will also evaluate […]
FDA approves label update to Novo Nordisk’s Tresiba diabetes drug
The FDA approved Novo Nordisk‘s (NYSE:NVO) request to include heart health data on the label of its Tresiba insulin degludec product. The Danish insulin-maker evaluated its Type II diabetes drug in a 7,637-patient trial, assessing the therapy for cardiovascular safety compared to insulin glargine. Novo Nordisk’s Devote trial met its primary endpoint after Tresiba demonstrated […]
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
The Japanese Ministry of Health, Labor and Welfare gave Novo Nordisk (NYSE:NVO) the green light to market its once-weekly type II diabetes drug, Ozempic, Reuters reported today. The pharma company’s drug, semaglutide, is a glucagon-like peptide-1 analog that mimics an intestinal hormone to trigger insulin production in people with diabetes. Novo Nordisk expects to launch Ozempic in Japan in […]
Meet the insulin-makers and device companies developing smart insulin pens
The global market for connected insulin pens could be worth up to $123 million by 2023, according to a report published this year by Research & Markets. Insulin pens, designed for people who control their diabetes with multiple daily injections instead of a pump or wearable patch, are portable devices that were first introduced in 1985 with […]
Novo Nordisk touts promising results from late-stage trial of oral diabetes med
Setting the stage for a battle with rival Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO) reported data this week from a late-stage trial of its oral formulation of semaglutide, a medication for people with Type II diabetes. The GLP-1 agonist is traditionally administered via injection. Both insulin-makers have approved versions of the injectable semaglutide, but Novo Nordisk is […]
Express Scripts to include Novo Nordisk’s once-weekly diabetes drug on 2018 formulary
Express Scripts, one of the nation’s largest pharmacy benefit managers, reportedly plans to include Novo Nordisk‘s (NYSE:NVO) once-weekly Type II diabetes, Ozempic, on its 2018 formulary. The move puts Ozempic directly in competition with Eli Lilly‘s (NYSE:LLY) once-weekly Trulicity drug. Both products will also go up against AstraZeneca‘s (NYSE:AZN) once-weekly Bydureon medication. All three drugs […]
Novo Nordisk’s once-weekly Type II diabetes med approved in Europe
The European Commission has approved Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide drug, Ozempic, as a treatment for adults with Type II diabetes. The GLP-1 analogue’s label in Europe recommends that the drug is given when metformin is contraindicated or not tolerated, Novo Nordisk reported today. The E.U. agency approved Ozempic for use in a multi-dose pre-filled pen, but […]